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INTRODUCTION 
According to recent statistics published by the American Heart 
Association, cardiovascular disease claims more than 930,000 lives each year. 
That is more than the next five leading causes of death combined. Major risk 
factors for developing cardiovascular complications include obesity, 
dyslipidemia, diabetes, age greater than 60, male gender, family history, and 
smoking3. The importance of smoking cessation is matched only by the gravity of 
the risk smoking itself presents. An estimated 20 to 30% increase in myocardial 
infarctions or ischemic heart disease has been exhibited even in nonsmokers 
exposed to substantial amounts of environmental tobacco smoke4. The lipophilic 
nature of the various polycyclic aromatic hydrocarbons (PAHs) found in tobacco 
smoke expedites their access into a cell, thereby intensifying their harmful effect.  
A well-conserved protein known as the aryl hydrocarbon receptor (AHR) 
mediates the response to such PAHs. The AHR is a ligand-dependent, bHLH-PAS 
transcription factor found throughout the body, including the heart, liver, lungs, 
and thymus5. Upon activation, it regulates the expression of its target genes by 
binding to xenobiotic response elements (XREs) on DNA. One important group 
of target genes is the xenobiotic-metabolizing enzymes that are up-regulated as an 
adaptive response to many environmental stressors. These enzymes shorten the 
half-life of the insulting stressor, thereby limiting its harmful effect. The bHLH 
(basic, helix-loop-helix) domain participates in homotypic dimerization 
interactions that position the basic region in place for contact with regulatory 
elements found in DNA. The PAS (Per-Arnt-Sim) domain functions as a surface 
  
2 
for the following: homotypic interactions with other PAS proteins, heterotypic 
interactions with chaperones like Hsp90, and interactions with activating ligands6.  
The unbound AHR is found in the cytoplasm of a cell, clustered with a 
dimer of Hsp90 and additional cellular chaperones such as ARA95-7. This 
complex, especially the binding with Hsp90, is thought to appropriately align a 
site on the AHR necessary for ligand binding. Subsequent binding of a ligand 
exposes a nuclear localization signal on the receptor, thereby promoting 
translocation of the complex into the nucleus. Upon entering the nucleus, the 
AHR dissociates itself from its chaperone proteins and forms a heterodimer with 
another bHLH-PAS protein, ARNT. ARNT is responsible for the direction of the 
ligand-bound AHR to specific enhancer elements on the DNA. The enhancer 
element to which the AHR/ARNT heterodimer binds is called a xenobiotic 
response element (XRE). The core XRE sequence is TNGCGTG, in which AHR 
binds TNGC and ARNT binds GTG. Binding of the AHR/ARNT complex to the 
XREs allows for enhanced transcription of specific target genes. Many of these 
genes are drug-metabolizing enzymes and include phase one enzymes (i.e. 
CYP1A1 and CYP1A2) and phase two enzymes (i.e. NADPH-quinone 
oxidoreductase and GST-1a). An additional protein known as the AHR repressor 
(AHRR) is up-regulated, and presumed to be involved in a negative feedback loop 
by competing with AHR for ARNT dimerization8.  
The known xenobiotic ligands for the AHR include PAHs (i.e. 3-
methylcholanthrene) and halogenated aromatic compounds (i.e. 2,3,7,8-
tetracholorodibenzo-p-dioxin or dioxin)6;9;10. The greatest sources for human 
  
3 
exposure stem from large-scale industrial processes, including the incomplete 
combustion of plastics and pulp and paper production. More common sources 
include cigarette smoke, exhaust fumes, diesel engines, cooked meat and fish, 
dairy products, and mother’s milk. Dioxin is the most studied xenobiotic ligand 
for the AHR. This halogenated aromatic compound binds solely to the AHR, is 
slowly metabolized by the body, and is thought to bind to the receptor with an 
even greater affinity than other PAHs6;9;10.  
Toxicological studies in which entire organisms were exposed to vast 
amounts of xenobiotics have confirmed that overactivation of the AHR leads to 
many systemic effects, including acute lethality, chloracne, immune suppression 
with thymic atrophy, and alterations in growth factors and cytokines6. 
Overexposure has also been linked to cancer and cardiovascular disease11-14. 
Cardiotoxicity due to TCDD overexposure was illustrated by a decrease in both 
heart rate and blood pressure6. 
Compared to the xenobiotic ligands, very little is known about the 
endogenous ligands for the AHR. This group of comparatively short-lived 
molecules is suspected to include 7-ketocholesterol15 and bilirubin16;17. AHR 
knockout mouse strains have been developed to explore what role the AHR plays 
in normal physiology. Although it was found that these mice were no longer 
susceptible to the effects of dioxin exposure, other serious physiologic problems 
arose. The knockout mice exhibited persistent fetal vasculature and liver 
morphology, compromised immune systems, and both structural and functional 
cardiac abnormalities18. Specifically in the mouse hearts, an observed increase in 
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the size of cardiac myocytes was consistent with hypertrophy 19. Although the 
molecular mechanism remains unclear, the results of these studies confirm that 
the AHR is necessary for growth, survival, and reproduction in the normal 
physiology of the mouse.   
Although the overactivation and knockout studies have provided great 
insight into the effects of extreme degrees of AHR activity, many questions are 
left unanswered by their results. One caveat of whole animal dosing experiments 
is their failure to target a specific cellular population, thereby blurring the line 
between cell autonomous and non-autonomous effects. My project aims to solve 
this problem by constructing a conditional transgene that drives constitutive 
activation of the AHR only in the cardiomyocyte, or any other desired specific 
cellular population. This approach utilizes the Green Fluorescent Protein (GFP) 
along with a cre-lox P system for detectable, site-specific activation of the AHR 
protein. The following paper describes the design strategy and construction of this 
type of AHR transgene.  
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MATERIALS and METHODS 
Antibiotic Selection 
The antibiotic Zeocin was added to LB agar plates for selection of colonies 
containing the pDRIVE vector. Ampicillin was used as a selectable marker for the 
remainder of the constructed plasmids.  
 
DNA isolation and purification 
QIAGEN Miniprep kits were used to isolate purified plasmid DNA from 
E. coli cells. The procedure is based on the alkaline lysis of bacterial cells 
followed by adsorption of DNA onto silica in the presence of high salt.  
Pelleted cells from the bacterial culture were resuspended in Buffer P1 (50 
mM Tris·Cl, pH 8.0; 10 mM EDTA; 100 µg/ml RNase A). The cells were then 
lysed under alkaline conditions upon addition of Buffer P2 (200 mM NaOH and 
1% SDS [w/v]). The lysate was subsequently neutralized with Buffer N3 
(proprietary mixture of guanidine hydrochloride, isopropanol, and other agents), 
which causes the genomic DNA, proteins, carbohydrates, and lipids to precipitate 
while re-naturing the plasmid DNA. After separation of the precipitate from 
DNA, the plasmid DNA was exposed to the silica-gel membrane and bound due 
to the high salt conditions. Buffer PB (proprietary mixture of guanidinium 
chloride, propan-2-ol, and other agents) and Buffer PE (proprietary mixture of 
ethanol and other agents) were used to wash the silica-gel membrane. The 
purified DNA was then collected by elution with Buffer EB (10 mM Tris·Cl, pH 
8.5). 
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Ethanol Precipitation 
An ethanol precipitation was performed to increase the concentration of the DNA 
sample. After the volume of the DNA sample was measured, the salt 
concentration was adjusted by adding 1/10 volume of 3 M sodium acetate, pH 5.2. 
Next, 2.5 volumes of 100% ethanol were added and the mixture was placed on ice 
for a minimum of 20 minutes. The DNA was pelleted by centrifugation, separated 
from the supernatant, and then washed with 1 ml of 70% ethanol. The sample was 
again centrifuged, separated from the supernatant, and allowed to air dry for 30 
minutes. The pellet was then resuspended in the appropriate volume of TE (10 
mM Tris-HCl, pH 8, with 1 mM EDTA). 
 
Gel Electrophoresis 
To determine the size and concentration of DNA fragments, DNA samples 
were loaded on 0.7%, 1.0%, or 2% agarose gels. For size determination, samples 
were run against a 1kb ladder (Invitrogen). For concentration determination, 
samples were run against either a high mass or low-mass ladder (Invitrogen), 
depending on the size of the fragment.  
The concentration of agarose in the gel was dictated by the size of the 
DNA fragments being separated. The agarose gels were prepared by dissolving 
the appropriate amount of agarose in 300 ml of 1X TAE buffer (40mM Tris; 
20mM acetic acid; 1mM EDTA). 15µl of 10mg/ml ethidium bromide was added 
for visualization under UV light. Approximately 50ml was poured for each gel. 
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Sources of plasmid components 
 Oligos inserted in ligation reaction with pBluescript II SK plasmid (pSK) 
were ordered from Invitrogen.  The CAG promoter was isolated from the 
pDRIVE-CAG vector (InvivoGen). The GFP was isolated from the pd2EGFP-1 
vector (BD Biosciences). The mouse β globin terminator and poly A addition 
sequence (gDEF) was obtained from Dr. Falck-Pedersen20.  
 
Spectrophotometric assay 
100 µl DNA samples were loaded into a 100 µL microcuvette in 1:25, 1:50, or 
1:100 dilutions with TE (1 M Tris-HCl, pH 8, with 100 mM EDTA). The assays 
were performed using a BioRad Spectrophotometer and the absorbency readings 
at 260λ and 280λ were recorded. Nucleic acid concentrations of dsDNA were 
determined by multiplying the 260λ absorbance reading by a mass/absorption 
conversion factor and by the dilution factor. The mass/absorption conversion 
factor used for dsDNA was 50.0 µg/ml. 
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RESULTS 
Design of conditionally activated DNA construct 
 The final conditional transgene expression construct should contain a 
ubiquitous promoter, a translational insulator flanked by two lox P sites, the 
coding region of the target gene, and a poly A addition signal (Figure 2, A).The 
CAG promoter is a very strong and ubiquitous promoter that will be used in my 
construct. It has been shown to drive expression in all tissues of transgenic mice 
with the exception of erythrocytes and hair21. This composite promoter combines 
the human cytomegalovirus immediate-early enhancer, a modified chicken beta-
actin promoter, and a 5’ untranslated region22. 
 The GFP marker will function as an insulator of translation as well as a 
selectable marker for those cells expressing the target genes driven by the CAG 
promoter. Important components include the EGFP coding region, a PEST 
sequence, and SV40 Poly A region. The PEST sequence destabilizes the protein, 
thereby reducing its half-life and preventing the toxic effects of an overabundance 
of GFP. The translational stop site (TGA) prevents the translation of the target 
gene until the GFP is acted upon by a cre-lox P gene switch approach. In the 
presence of the cre-recombinase, the DNA encoding GFP between the lox P sites 
will be looped out, allowing transcription and translation of the target gene 
(Figure 2, B). A cell-specific promoter can be used to drive the Cre, thereby 
enabling expression of the target gene in a specific cell population.  
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 The mouse β−globin transcriptional terminator and poly A addition signal, 
gDEF, will be included at the 3’-end of the target gene coding region to provide 
for mRNA stability 20.  
 
Construction of pBVD1 
 A 98 base pair oligo sequence was designed to include HindIII overhangs, 
two lox P sites, and additional restriction sites for subsequent cloning steps. The 
BVD1 plasmid results from the insertion of this oligo sequence into the 
pBluescript II SK plasmid (Figure 3, A and B). The pSK was first digested and 
linearized with HindIII. The complementary oligos were annealed to each other 
and then ligated to the resulting overhang sites on the pSK left by the HindIII 
digestion. A size shift of approximately 100 base pairs on a 2% agarose gel and 
the appearance of the AgeI and AflII restriction sites verified insertion of the oligo 
sequence. Proper orientation was confirmed by DNA sequencing. 
 
Construction of pBVD2 
 The CAG promoter will be used to drive expression of the target genes in 
all tissues of transgenic mice with the exception of erythrocytes and hair. The 
BVD2 plasmid results from the insertion of the CAG promoter sequence into 
pBVD1 (Figure 4, A and B). The 1.6 kb CAG promoter sequence was first 
excised from the 6353 bp pDRIVE-CAG plasmid by PstI and NcoI. The 5’  
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overhang left by the NcoI digest was blunted using T4 DNA polymerase. BVD1 
was prepared for ligation by digestion with PstI and EcoRV.  
 
Construction of pBVD3 
 The GFP marker will function as an insulator of translation as well as a 
selectable marker for those cells expressing the target genes driven by the CAG 
promoter. The BVD3 plasmid results from the insertion of the GFP sequence into 
BVD2 (figure 5, A and B). The 1.2 kb GFP sequence was first excised from the 
4.3 kb pd2EGFP-1 plasmid by BshT1 (an isoschizimer of AgeI) and BspT1 (an 
isoschizimer of AflII). BVD2 was prepared for ligation by digestion with BshT1 
(AgeI) and BspT1 (AflII).  
 
Construction of pBVD4 
 The gDEF sequence will function as a strong transcriptional terminator 
and poly A addition signal20. The BVD4 plasmid results from the insertion of the 
gDEF sequence into BVD3 (figure 6, A and B). The 1.5 kb gDEF sequence was 
first excised from the pMK1 plasmid by SalI and NotI. The 5’ overhang left by 
the NotI digest was blunted using T4 DNA polymerase. BVD 3 was prepared for 
ligation by digestion with SalI and Acc65 I (an isoschizimer of KpnI). The 5’ 
overhang left by the Acc65I digest was blunted using T4 DNA polymerase.  
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DISCUSSION 
 Although time restraints have prevented me from inserting the AHR 
sequence into the pBVD4 plasmid, the stage has been set to explore the effects of 
conditional, constitutive activation of the AHR specifically in the cardiomyocyte 
of the mouse. Once the construct is complete and a stable transgenic line is 
produced, the cre-lox P system and GFP protein will allow those who continue 
my project to track AHR expression under a UV fluorescent microscope. I expect 
chronic, supraphysiologic activation of the AHR signaling pathway in the 
cardiomyocyte to be sufficient to perturb normal cardiac homeostasis. An 
additional exciting and valuable element of my construct lies in the research 
possibilities it has allowed for others. With my construct, essentially anyone with 
the appropriate cell-specific promoter driving cre-recombinase can conditionally 
and detectably activate any gene of interest in a specific cellular population.  
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APPENDIX A 
 
Figure 1: AHR mechanism upon xenobiotic activation 
 Unbound AHR is found in the cytoplasm of the cell, clustered with Hsp90 
and other chaperone proteins. Upon ligand activation, a nuclear localization signal 
on the receptor is exposed, thereby promoting translocation of the complex into 
the nucleus. The AHR dissociates itself from its chaperone proteins upon entering 
the nucleus, and forms a heterodimer with ARNT. Binding of the AHR/ARNT 
complex to the XREs allows for enhanced transcription of specific target genes, 
including CYP1A1 and AHRR.  
 
 
Figure 2: Effect of cre-recombinase on generic conditional transgene 
A.  
 Schematic diagram of generic conditional transgene before cre-
recombinase. The insulator, flanked by two lox P sites, contains a stop site that 
prevents the transcription of the gene of interest. 
B. 
 Schematic diagram of generic conditional transgene after cre-recombinase. 
The cre-recombinase has acted at the lox P sites to excise the insulator, thereby 
allowing the transcription and translation of the gene of interest.  
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Figure 3: Insertion of oligo sequence into pSK 
A. 
 Oligo sequence designed for insertion into pSK. Two identical 34 base 
pair lox P sequences (red) flank the AgeI and AflII restriction sites (red). The 
HindIII overhangs on each side of the oligo sequence were designed to 
complement the HindIII overhangs on the pSK during the ligation reaction.  
 
B.  
 Plasmid map of pBVD1. Important sites on the oligo insert are labeled in 
red. PstI and EcoRV sites will be used for subsequent insertion of CAG promoter.  
 
 
Figure 4: Insertion of CAG promoter into pBVD1 
A. 
 Schematic diagram of strong, hybrid CAG promoter. This composite 
promoter combines the human cytomegalovirus immediate-early enhancer 
(dashed), a modified chicken beta-actin promoter (dotted), and a 5’ untranslated 
region. PstI and NcoI sites were used for the ligation with PstI and EcoRV sites 
on the pBVD1.  
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B.  
 Plasmid map of pBVD2. The CAG promoter and its important sites are 
labeled in blue. AgeI and AflII sites will be used for subsequent insertion of GFP.  
 
 
Figure 5: Insertion of GFP into pBVD2 
A. 
 Schematic diagram of GFP.  Important components include the EGFP 
coding region (solid), PEST sequence (dashed), and SV40 Poly A addition signal 
(crossed). Translational start and stop sites are indicated. AgeI and AflII sites were 
used for the ligation with AgeI and AflII sites on the pBVD2.  
 
B. 
 Plasmid map of pBVD3. The GFP and its important sites are labeled in 
green. SalI and KpnI sites will be used for subsequent insertion of gDEF. 
 
 
Figure 6: Insertion of gDEF into pBVD3 
A.  
Schematic diagram of gDEF. The sequence includes a strong, mouse β-
globin transcription terminator as well as a poly A addition signal for message 
stability.  
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B.  
 Plasmid map of pBVD4. The gDEF is labeled in purple. The restriction 
sites between the lox P and gDEF can be used for subsequent insertion of the 
AHR, or any other target gene.  
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APPENDIX B 
 
Figure 1. 
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Figure 2. 
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Figure 3.   
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Figure 4.      
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Figure 5.      
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Figure 6.      
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